Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BioNTech

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Salon

What's Happening With BioNTech SE Shares?

Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Benzinga

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Reuters

HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings for BioNTech

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Benzinga

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have

Benzinga

Here's Why Matinas BioPharma Shares Are Rising

Matinas BioPharma Holdings Inc (NASDAQ: MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines.

Benzinga

Sadiq Khan calls on leading vaccine manufacturers to share Covid jab blueprints with world

Exclusive: Sadiq Khan, alongside mayors of New York and Johannesburg, urged companies ‘to do all you can’ to promote vaccine equity and ‘help stop the unnecessary loss of life’

The Independent UK

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters

BioNTech Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

Benzinga

Recap: BioNTech Q4 Earnings

BioNTech (NASDAQ:BNTX) reported its Q4 earnings results on Wednesday, March 30, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

The Independent UK

BioNTech's quarterly profit soars on COVID-19 vaccine demand

BioNTech has reported another quarter of strong earnings growth

Benzinga

Earnings Outlook For BioNTech

BioNTech (NASDAQ:BNTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will report an earnings per share (EPS) of $8.19.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

Benzinga

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

Caixin Global

Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

The Independent UK

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

Financial Times

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Asharq Al-Awsat

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.